Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell Transplantation by Hu, Bo & Liu, Haiyan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Donor Natural Killer Cells and Their Therapeutic
Potential in Allogeneic Hematopoietic Stem Cell
Transplantation
Bo Hu and Haiyan Liu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69684
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Bo Hu and Haiyan Liu
Additional information is available at the end of the chapter
Abstract
Natural killer (NK) cells were first identified and named for their “natural” cytotoxicity to 
reject bone-marrow allografts in lethally irradiated mice. Different from T cells, NK cells 
require no prior sensitization or immunization to lyse transformed or virally infected tar-
get cells and are non-major histocompatibility complex (MHC)–restricted. However, recent 
progress in understanding of NK cells biology has proved that NK cells share some simi-
lar characteristics with T cells. During development, NK cells also undergo “education” 
according to “missing self” principle, thereby become mature and acquire effector function. 
The discovery that NK cells are able to “remember” prior certain stimulations indicates 
they may also contribute to adaptive immunity. After hematopoietic stem cell transplanta-
tion (HSCT), NK cells are the first donor-derived lymphogenous cells to reconstitute and 
alloreactivitiy of donor-derived NK cells have been shown to mediate graft-versus-leuke-
mia (GvL) effect rather than to induce graft-versus-host disease (GvHD). These properties 
make donor-derived NK cells appealing for applications to benefit the outcome of HSCT. 
Here, we will review the improved understanding of NK cell biology, discuss characteris-
tics of donor-derived NK cells which are associated with beneficial outcome of HSCT and 
explore novel methodologies that enhance the therapeutic effect of donor NK cells.
Keywords: hematopoietic stem cell transplantation, NK cells, immunotherapy, leukemia, 
cytomegalovirus, immune memory
1. Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most effec-
tive therapy for leukemia and other malignant diseases [1]. Its major complications are 
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graft-versus-host disease (GvHD), infections, and leukemia relapse [2, 3]. Natural killer 
(NK) cells represent a key component of innate lymphoid cells and provide defense against 
microbial infection and malignant transformation by direct cytotoxicity and cytokine pro-
duction [4, 5]. The role of NK cells in allo-HSCT was first demonstrated in haploidentical 
transplants [6]. During T-cell depleted haploidentical HSCT, the rapid recovery of donor-
derived NK cells mediated potent graft-versus-leukemia (GvL) effect. Importantly, allore-
active NK cells mediated beneficial GvL effect without the occurrence of GvHD, which was 
consistently caused by donor T cells [7, 8].
Although the rapid reconstitution of donor NK cells plays a critical role in their GvL effect 
of the graft, they still take about 6 months or more to acquire maturation phenotype and full 
functionality [9]. This immaturity and insufficient education status may result in impaired 
function of donor NK cells in the early stage post transplantation. In addition, since the allo-
reactivity of donor NK cells was proved to account for the clinical benefit, genotyping the 
polymorphisms of killer cell immunoglobulin-like receptor (KIR), human leukocyte antigen 
(HLA) and Fcγ receptor (FcγR) are important for donor selection to maximize the GvL effect 
[10]. Sufficient numbers of allogeneic NK cells with high purity can also be generated and 
expanded through several sources including peripheral blood mononuclear cells, umbilical 
cord blood (UCB), and bone marrow–derived CD34+ cells to be adoptively transferred after 
allo-HSCT [11, 12]. Many approaches involving the use of different feeder cells, engineered 
feeder cell, and cytokine stimulation were utilized to achieve sufficient numbers of donor NK 
cells with the most efficient GvL effect and clinical responses [13, 14]. Moreover, seven NK 
cell lines have been established to be used effectively during allo-HSCT, among which, NK-92 
cell line has been shown to be safe and efficient in clinical trials [15–17]. Recently, genetic 
modification of NK cells has also been developed to enhance their function. Both gene transfer 
of chimeric antigen receptors (CARs) and expression of cytokine transgenes in NK cells are 
performed to improve the efficacy of NK cells therapy [18–20]. Furthermore, although tra-
ditionally considered as members of innate branch, increasing studies suggest that NK cells 
also “remember” prior certain stimulation like antigens, cytomegalovirus (CMV), or cytokines 
[21–26]. It draws particular interest to evaluate the role of adoptively transferred memory-like 
donor NK cells in allo-HSCT. Based on these research progresses of donor NK cell-mediated 
immunotherapy during allo-HSCT, in this chapter, we will describe the present state of donor 
NK cell therapy during allo-HSCT and its future direction aiming to improve therapeutic 
benefit of donor NK cells.
2. Overview of natural killer cell biology
NK cells represent a key component of innate lymphoid cells (ILC) and provide defense against 
microbial infection and malignant transformation. They belong to ILC1 group (according to 
their ability to produce type1 cytokine and transcription factors, they required for differen-
tiation) and are so named for their capacity to mediate cytotoxicity toward cancer cells and 
virus-infected cells without prior sensitization [27–29]. NK cells constitute 10–15% of human 
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peripheral blood lymphocytes and are defined by expression of CD56 without T cell marker 
CD3 [30]. Human NK cells can be further divided into two different subsets depending on the 
expression density of CD56 and CD16 [30]. The CD56dim CD16bright subsets account for majority 
(90%) of peripheral blood circulating NK cells and display cytotoxic function [31, 32], whereas 
CD56bright CD16bright subsets are predominantly found in lymph nodes and produce abundant 
amounts of inflammatory cytokines such as interferon-γ (IFN-γ), tumor necrosis factor alpha 
(TNF-α), tumor necrosis factor beta (TNF-β), IL-10, IL-13, granulocyte-macrophage colony 
stimulating factor (GM-CSF), etc., thereby promote adaptive immune responses [31, 33].
2.1. Natural killer cell receptors
NK cells immune function is mediated through an array of inhibitory and activating cell sur-
face receptors. There are three main types of receptor families: KIR, C-type lectin receptors 
and natural cytotoxicity receptors (NCR) [34].
KIRs are proteins belonging to immunoglobulin superfamily that are encoded by a gene com-
plex located on chromosome 19q13.4. Individuals may have up to 15 different KIR genes and 
two pseudogenes encoding for relevant receptors [35]. KIRs express stochastically on mature 
NK cells and recognize HLA molecules in a manner independent of antigen presentation. When 
bound to their ligands, these receptors transmit either inhibitory or activating signals. KIR genes 
are inherited as haplotypes due to the different number of KIR gene, and their high degree 
of diversity induced by various KIR gene content and allelic polymorphism [36]. Two major 
groups of KIR haplotypes have been distinguished based on gene content. Group A haplotypes 
contain a fix number of genes that are mainly inhibitory KIR, including KIR2DL1, KIR2DL3, 
KIR3DL1, KIR2DS4, and the pseudogene KIR2DP1. On the other hand, group B haplotypes are 
alterable both in numbers and content of KIR gene and have at least one of the following genes: 
KIR2DL2, KIR2DL5A, KIR2DL5B, KIR2DS2, KIR2DS5, and KIR3DS1 [37]. Group B haplotypes 
contain more activating KIR (up to 5) compared with group A haplotypes (only one).
C-type lectin receptors are heterodimers and comprise of two subunits including CD94 protein 
and a C-type lectin natural killer group 2 (NKG2) molecule [38]. The gene of this receptor family 
located on chromosome 12 encoding six different NKG2 proteins: NKG2A, NKG2C, NKG2E, 
NKG2F, NKG2B, NKG2H, as well as CD94 protein. Among these receptors, CD94/NKG2A and 
CD94/NKG2B are inhibitory receptors and bind HLA-E, whereas other receptors are activating. 
Activating receptor NKG2D also belongs to NKG2 family and is expressed on the surface of NK 
cells as a homodimer. NKG2D can recognize two different families of cognate ligands includ-
ing nonclassical major histocompatibility complex (MHC) molecules (MIC-A and MIC-B) and 
UL16 binding protein family [39, 40]. The expression of NKG2D ligands is upregulated under 
the influence of cellular stress such as viral infection, inflammation, and tumor formation.
Natural cytotoxicity receptors including NKp30, NKp44, and NKp46 are activating receptors 
expressed on the surface of NK cells [41]. NKp30 can recognize ligands expressed on tumor cells 
such as the nuclear factor HLA-B-associated transcript-3 (BAT-3) and B7-H6 [42]. NKp30 also 
binds to viral ligands (CMV pp65 protein) [42]. Both NKp46 and NKp44 bind to viral-derived 
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proteins such as influenza hemagglutinin (HA) [43, 44]. Moreover, NKp44 has been shown to 
recognize the envelope glycorpoteins from West Nile and dengue viruses and NKp46 has been 
shown to recognize vimentin expressed on Mycobacterium tuberculosis–infected human mono-
cytes [45]. However, the ligands of NCR have not been well identified yet.
2.2. Natural killer cell function
Upon education, the “licensed” NK cells acquire cytotoxic activity toward target cells lack-
ing self MHC class-I molecules, meanwhile they are tolerant to normal cells expressing self 
MHC class-I molecules, namely “missing self” hypothesis. However, this hypothesis seems to 
oversimplify NK function regulation. Activating receptors have also been shown to play an 
important role to make the decision “to kill or not.” For example, during murine allo-HSCT 
model, alloreactive donor NK cells do not respond to host’s epithelial cells although donor 
NK cells lacking inhibitory receptors specific for host MHC class-I, mainly due to their low 
expression level of ligands specific for activating receptors of donor NK cells [6]. In some 
cases, the extremely high strength of activating signals may even overcome weaker inhibitory 
signals resulting in activation of NK cells [46, 47]. Therefore, triggering of NK cell activation is 
finally depended on the balance of activating and inhibitory receptors of NK cells.
Once NK cells are activated, they respond to target cells with function similar to CD8+ T cells. 
Immune synapse forms and perforin and granzyme are released to induce apoptosis of tar-
get cells through activation of Caspase 3 [48]. NK cell activation also upregulates the expres-
sion of factor associated suicide (FAS) and tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) and kill the target cells through Caspase 8 activation induced apoptosis [49, 
50]. Furthermore, NK cells can also crosstalk with adaptive immune system through cytokine 
release and antibodies. Virus infected cells and tumor cells are recognized by B cells. These cells 
are then marked with antibodies covering their cell surface. NK cells recognize and bind to these 
cells through the interaction between activating receptor CD16 and the Fc end of antibodies [51]. 
This recognition mediates a potent activating signal in NK cells and results in target cells lysis. 
Moreover, NK cells are able to secret cytokines and chemokines upon activation, such as TNF-α, 
IFN-γ, regulated upon activation, norma, T-cell expressed and secreted (RANTES), GM-CSF, 
macrophage inflammatory protein-1-alpha and beta (MIP1-α and-β). NK cells can promote den-
tritic cells maturation through TNF-α and IFN-γ secretion [52]. IFN-γ production also affects 
helper T cell subset 1 (Th1) migration and effector function. Additionally, Th1 polarization in 
secondary lymphogenous organs is enhanced by IFN-γ secretion [53]. Thus, IFN-γ secretion 
of NK cells is critical for forming a bridge between the innate and adaptive immune responses.
3. Natural killer cell development and education
3.1. Natural killer cell development
NK cells develop from CD34+ hematopoietic progenitor cells which can also give rise to T cells, 
B cells, and dendritic cells [54]. Particular transcription factors such as purine rich box-1 (PU.1), 
E26 transformation-specific (ETS-1), thymocyte selection-associated HMG box factor (TOX), the 
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mammalian transcription factor E4 binding protein 4 (E4BP4), eomesodermin (Eomes), and T-box 
transcription factor (T-bet) are required for NK cell maturation stages [55–58]. Among these tran-
scription factors, Eomes and T-bet are responsible for cytotoxicity and IFN-γ production in mature 
NK cells [59]. Furthermore, CD56dim NK cells express higher levels of T-bet and lower levels of 
Eomes than CD56bright NK cells, and T-bet/Eomes ratio increases with NK cells maturation [60]. A 
central cytokine required for NK cell development in vivo is IL-15, as mice lacking IL-15, CD122 
(IL-15β-chain receptor), interleukin 15 receptor alpha (IL-15Rα), or signal transducer and activa-
tor of transcription 5 (STAT5) do not generate mature NK cells [61]. Stem cell factor (SCF), IL-7, 
and fms-like tyrosine kinase 3-ligand (Flt3-L) are also necessary for NK cell maturation since they 
induce pro-NK cell to express CD122 and CD132 (the common γ-chain receptor) so as to render 
cell to respond to IL-15 [62, 63]. Intriguingly, IL-15 is primarily accompanied by IL-15Rα and trans-
presented by accessory cells to support NK cell differentiation and proliferation in vivo rather than 
affecting NK cell in a soluble form [64].
After maturation in the bone marrow, NK cells migrate to peripheral circulation and take part 
in the defense against cancers and viral infections. Two major subsets in the peripheral blood 
are CD56dim and CD56bright NK cells [30]. These subsets differ in receptor expressions, functional 
capabilities, and tissue distribution. Although CD56dim NK cells have been considered to be 
cytotoxic population, it is now clearly proved that they also produce large amounts of cytokines 
upon receptor-induced NK cell triggering [65, 66]. These functional differences can be partly 
explained by different expression pattern of surface receptors. CD56dim NK cells express CD16, 
KIR and other activating or inhibitory receptors which are critical for their cytolytic functions, 
whereas CD56birght NK cells rarely express KIR and CD16 [67]. Interestingly, CD56bright NK cells 
could express KIR and CD16 after stimulation of IL-2 or IL-12 suggesting CD56bright NK cells 
are NK cell subsets in the stage of maturation [68, 69]. Thereafter, recent studies confirm that 
CD56dim NK cells indeed differentiate from CD56bright NK cells which display longer telomerase 
[70]. Due to different expression of chemokine receptors and adhesion molecules, CD56dim NK 
cells account for around 90% of peripheral blood NK cells, while CD56bright NK cells primarily 
exist in secondary lymphoid tissues or decidual tissues during early pregnancy [71].
3.2. Generation of memory-like natural killer cells
Immune memory is previously considered as an exclusive property of T cells and B cells and 
defined as quicker and more robust responses to recurrent antigens [72]. However, accumulat-
ing evidence proved NK cell also have memory-like feature after certain modes of challenge 
including antigen-specific stimulation and antigen-independent activation. The hepatic NK cell 
memory was first observed by the Von Andrian’s group [73]. They found NK cells can mediate 
delayed-type hypersensitivity (DTH) reactions in Rag2−/− mice model. These hapten-specific 
NK cells are exclusively recruited to the liver and identified as CD49a+ DX5− NK cell popula-
tion, expressing chemokine receptor CXCR6 [21, 73, 74]. The mechanism that generate this 
antigen-specific NK cells whose receptors cannot be somatically rearranged remain unknown. 
Moreover, similar hepatic memory response has not been proved to occur in humans.
Another differentiation pathway for antigen-specific NK cell memory response is CMV infec-
tion. CMV-triggered NK cell memory was first observed by the Lanier laboratory demonstrating 
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that Ly49H+ NK cells can rapidly expand and response robustly after murine CMV (MCMV) 
re-infection [75]. NK cell co-activating receptor DNAX adhesion molecule-1 (DNAM-1) is 
required for the initial expansion of MCMV-induced memory NK cells [76]. Furthermore, 
transcription factor Zbtb32 and pro-inflammatory cytokine pathway also play important 
role in MCMV-induced expansion [77, 78]. In human, natural killer Group 2, member C 
positive (NKG2C+) NK cells also expand during acute human CMV (HCMV) infection and 
display a CD56dimCD57+NKG2A− phenotype [79, 80]. These HCMV-induced memory NK 
cells have increased expression of IFN-γ, which may be induced by epigenetic remodeling of 
IFNG locus [81, 82]. The role of HCMV-induced NK memory during HSCT will be described 
in section 6 of this chapter.
Antigen-independent NK cell memory response was first observed by the Yokoyama labo-
ratory [24]. They showed mouse NK cells which were pre-activated with the combination of 
IL-12/15/18 overnight produced increased level of IFN-γ upon re-stimulation. Additionally, 
these cytokine-induced memory-like NK cells displayed enhanced proliferation and upregu-
lation of CD25 expression in response to re-stimulation with cytokines [24, 25]. Intriguingly, 
human NK cells also can give rise to cytokine-induced memory-like NK cells with similar 
key properties [26]. Series of studies explored the antitumor responses of cytokine-induced 
memory-like NK cells, and we will discuss their role during HSCT in section 7 and 9 of this 
chapter.
3.3. Natural killer cell education
3.3.1. Inhibitory receptors are critical for natural killer cell education
The genes encoding for KIR are located on chromosome 19, while HLA genes are on chro-
mosome 6 [83]. Therefore, KIR genes and HLA genes are inherited independently, and this 
randomness may result in the expression of KIR on NK cells in the absence of their corre-
sponding HLA ligands, thereby NK cells may have chance to attack normal cells. In fact, NK 
cells are tolerant to our body most of the time. It is interesting to understand how NK cells are 
educated to become tolerant? Inhibitory receptors have been shown to play an important role 
in this education process. During NK cell maturation, when the inhibitory receptors recog-
nize self-MHC class I, the stochastic expression of KIR genes is switched off, and signals are 
transmitted to promote NK cell maturation and generate effector function. Oppositely, when 
the inhibitory receptors of NK cells fail to recognize self-MHC class I, they remain in a state of 
hyporesponsiveness and are not able to attack normal autologous cells [35, 84]. Collectively, 
only NK cells expressing “at least one” self-recognizing inhibitory receptor are “licensed” and 
acquire effector function, whereas “unlicensed” NK cells that recognize non-self-MHC are 
hyporesponsive and tolerant to normal cells. This process of “licensing” was proved in “pep-
tide transporter-associated antigen processing” (TAP)-deficient patients [85]. Cells from these 
patients hardly express HLA class I molecules on their surface, thereby potentially render 
self-cells to be targets of NK cells. However, most of these patients do not have autoimmune 
disorders because of the hyporesponsiveness of NK cells. Additionally, NK cells isolated from 
TAP-deficient patients are also unresponsive to autologous HLA class I-negative B lympho-
blastoid cell lines [86].
Natural Killer Cells112
3.3.2. The state of “unlicensed” natural killer cells is reversible
It is important to note that the hyporesponsive state of “unlicensed” NK cells is reversible. 
During viral infection, “unlicensed” NK cells regain cytotoxic activity and are even more effec-
tively in controlling murine cytomegalovirus (MCMV) infection compared with “licensed” 
NK cells owing to the lack of inhibitory effect of self MHC class-I expression on target cells 
[87]. The activity of “unlicensed” NK cells can also be restored after in vitro culture in the 
presence of IL-2 or IL-12+IL-18 or through activating receptors mediated strong signals [88].
The education process is more complex during allo-HSCT as donor-derived progenitors 
of NK cells posses both possibilities to undergo either donor type or host type education. 
Besides this, adoptively transferred mature NK cells can undergo “re-education” following 
MHC mismatched HSCT. It is now believed that donor HSC-derived NK cells generate a KIR 
repertoire of donor type, thanks to the high number of infused donor cells during haplo-
HSCT and both nonhematopoietic as well as hematopoietic cells may present self MHC class-I 
molecules to precursors of NK cells thereby are involved in NK cell education [34, 89].
4. Donor natural killer cell reconstitution after hematopoietic  
stem cell transplantation
NK cells need to develop in vivo to acquire effector function following HSCT. Accordingly, they 
are the first donor-derived lymphogenous cells to reconstitute and can be detected as early as 
the first month post-transplant [90]. The reconstitution kinetics and functional properties of NK 
cells are variable due to the primary activity of NK cells in the graft and different graft source 
including bone marrow, G-CSF-mobilized peripheral blood stem cell, and UCB. Series studies 
demonstrated that different grant source did not affect the rate of NK cell reconstitution and 
during the early stage post-HSCT, the primary NK cell subsets were CD56bright donor NK cells 
[91, 92]. These results indicated that the early reconstituting NK cells after HSCT were mainly 
generated from the differentiation and maturation of NK precursors but not the expansion of 
mature NK cells in the graft. Nevertheless, the expansion of adoptive transferred NK cells also 
influences the reconstitution of donor NK cells since Eissens et al. find that in HLA-matched allo-
geneic peripheral blood stem cell transplantation, CD3+/CD19+-depleted grafts which contain 
more mature NK cells than CD34+-selected grafts lead to more rapid NK cell reconstitution [93].
Although donor-derived NK cells are observed very early post-HSCT, they have an immature 
CD56bright KIR− NKG2A+ phenotype for at least 3-6 months [94]. Interestingly, the ability of 
these immature CD56bright NK cells to produce IFN-γ is significantly impaired in response to 
tumor cell line or primary leukemia cells [95, 96]. The expression of T-bet and mucin-containing 
domain-3 (Tim-3) is much lower in the patients post-HSCT compared with the healthy individ-
uals [97]. Both of these two molecules are critical for induction of IFN-γ production, thus their 
reduced expression may partly account for the decreased recovery of cytokine production.
It is difficult to clearly define the effect of T cell content in the graft on NK cell reconstitution 
as it is also depended on immunosuppressive therapy. By far, graft T cell content is thought to 
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significantly influence functional reconstitution of NK cells rather than numerical reconstitu-
tion. One study observed donor-derived NK cells reconstitution following HSCT with three 
different kinds of donor source including T-cell-replete adult grafts, T-cell-deplete adult grafts, 
and UCB [95]. Both of the T-cell-replete group and UCB group were treated with immuno-
suppression. They found KIR expression in T-cell-replete group was the highest among these 
three groups indicated donor-derived NK cells in this group may have better effector func-
tion. Accordingly, in an earlier study by the same group, they found IFN-γ production was 
more potent following HSCT with T-cell-replete grafts compared to T-cell-deplete transplan-
tation [98]. These results were consistent with the observations by Nguyen et al. which dem-
onstrated that without immunosuppression, recovery NK cells in the partial T-cell-depleted 
group had lower cytotoxicity than NK cells in the full T-cell-depleted group [92]. In summary, 
graft T cell content trends to enhance functional reconstitution of NK cells irrespective of 
immunosuppression. This promotion effect may be due to activation from T-cell-derived IL-2, 
or stimulation from other inflammatory cytokine such as IL-12 and IL-18, which are increased 
following donor T cell engraftment. Finally, CMV infection and GvHD may also have potent 
effect on NK cell reconstitution, and we will discuss this in the following sections.
5. Association between natural killer cell alloreactivity  
and graft-versus-leukemia effect
5.1. The complexity of hematopoietic stem cell transplantation may affect  
the graft-versus-leukemia effects of alloreactive natural killer cells
HSCT is well-established curative treatment for hematologic malignances. The major limitation 
of HSCT is the absence of HLA-matched donor. Therefore, the HLA-haploidentical relatives are 
increasingly used as donor sources of HSCs. During the haplo-HSCT, donor and recipient share 
one identical HLA haplotype, while other haplotype is fully mismatched [99]. The GvL effect 
of NK cells was first observed in a landmark study which demonstrated that NK cells rapidly 
reconstituted and displayed potent anti-leukemia activity after extensive T-cell depleted haplo-
HSCT [6]. After inhibitory receptor KIR was identified as a mediator of missing-self response, 
the GvL effect of NK cells was assumed to be mainly due to mismatches between donor KIR 
and recipient HLA class I which increase NK cell function thereby effectively lyse residual 
leukemia cells in the recipient. This hypothesis was first verified by Ruggeri L et al. [100]. They 
isolated donor-derived NK cells from haplotype-mismatched HCT recipients and tested their 
cytotoxicity toward recipient lymphocytes. Their results demonstrated donor alloreactive NK 
cells indeed effectively killed recipient myeloid leukemia cells. The follow-up study of this 
group demonstrated therapeutic utility of NK cell alloreactivity. They found transplants with 
KIR ligand mismatch were associated with decreased probability of relapse and increases in 
disease-free survival in the absence of GvHD [6].
Series studies subsequently tested NK cell alloreactivity-mediated GvL effect in the KIR 
ligand incompatibility model. However, not all studies supported the benefit role of alloreac-
tive NK cells. During haplotype-HCT with less T cell depletion, KIR ligand mismatch patients 
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even developed more acute GvHD (aGvHD), and the overall survival was poor. In a cohort 
using unrelated donors, no effect of predicted NK cell alloreactivity was observed, whereas in 
another similar cohort with T-cell depletion, KIR ligand mismatch prolonged overall survival 
[101, 102]. Frag et al. examined the clinical impact of NK cell alloreactivity in over 1500 unre-
lated transplants and found KIR ligand mismatch was not associated with relapse prevention 
[103]. In a retrospective study, data from 2062 unrelated transplant recipients were analyzed 
for acute myelocytic leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic 
syndrome (MDS) [104]. Missing one or more KIR ligands in the recipient were associated 
with less relapse in patients with early myeloid leukemia and in CML patients during first 
chronic phase. Nevertheless, KIR ligand mismatch was also associated with an increased risk 
of chronic GvHD (cGvHD) in CML patients.
The effect of NK alloreactivity in recipients of UCB grafts has also been tested. Willemze 
et al. evaluated the impact of KIR ligand incompatibility in recipients of UCB grafts with 
T-cell depletion and found KIR ligand mismatch was associated with relapse prevention and 
improved overall survival [105]. However, Brunstein et al. reported different results [106]. 
They investigated the impact of KIR ligand mismatch in patients of UCB grafts after different 
intensity conditioning regimens. After myeloablative conditioning, KIR ligand mismatch did 
not exert protective effect on GvHD, relapse, transplantation-related mortality, or survival. 
Following reduced intensity conditioning, KIR ligand mismatch patients developed more 
aGvHD and poorer overall survival.
The different results among these studies using either adult grafts or UCB grafts may be 
explained by the complexity of HCT, such as variable preparative regimens, donor sources, 
and degree of HLA mismatch with the donor. For instance, the degree of T-cell depletion 
was different among these studies, the grafts were extensively T-cell depleted in some stud-
ies, whereas only were partially depleted in others. T cell content may outcompete NK cells 
for cytokines and thereby influence the beneficial effect of alloreactive NK cells. Additionally, 
different intensity of preparative regimens also affects numeral and functional reconstitu-
tion of alloreactive NK cells after HSCT thus influences HSCT outcomes. Finally, the origin 
of leukemic blasts also affects HSCT outcomes. No beneficial effects of alloreactive NK cells 
in adult acute lymphoblastic leukemia (ALL) patients were observed probably due to the lack 
of expression of activating ligands [100]. However, allorecative NK cells have been proved to 
positively affect the outcome of HSCT in children with ALL [107]. Accordingly, the intensity 
of HLA expression on the leukemic lymphoblasts was shown to be critical for NK-mediated 
cytotoxicity in an experimental study [108].
5.2. Donor killer immunoglobulin-like receptors affect beneficial effects of alloreactive 
natural killer cells and outcome after hematopoietic stem cell transplantation
As we have mentioned above, KIR genes can be simplified into two main haplotypes: haplo-
type A and haplotype B. A hapltotype consists of main inhibitory KIR and single-activating 
KIR, KIR2DS4. B haplotype contains variable KIR gene encoding both inhibitory and activat-
ing KIRs which can be further divided into either centromeric (Cen) or telomeric (Tel) regions. 
The role of these haplotypes in HSCT is also evaluated. Mc Queen et al. first demonstrated 
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grafts from KIR A/A genotype donors into KIR B recipients resulted in poorer survival in HLA-
matched T-cell-replete sibling transplants [109]. In contrast, Stringaris et al. reported trans-
plants from KIR B haplotype donors including genes for KIR2DS1, KIR3DS1, and KIR2DL5 
improved overall survival and prevented relapse specific for AML patients with T-cell deple-
tion during HLA identical siblings HSCT [110]. A larger cohort was performed to further 
evaluate the effect of KIR B haplotype in AML patients. The results indicated that grafts from 
donors with KIR B haplotype significantly reduced the risk of relapse and improved overall 
survival [111]. A follow-up study expanded numbers of AML patients with T-cell-depleted 
unrelated donor transplants and found that donor KIR B haplotype-mediated relapse pre-
vention was enhanced in recipients who have HLA-C1 alleles rather than C2 homozygous 
recipients [36]. Michaelis SU et al. reported transplants from KIR B haplotype donors resulted 
in better HSCT outcome in ALL patients [112].
Collectively, it is logical to hypothesize that the presence of activating KIR in donor KIR B 
haplotype is favorably associated with better transplant outcome. However, it is difficult to 
evaluate the contribution of each activating KIR to relapse protection and better overall sur-
vival due to their unknown ligands. KIR2DS1 has been proved to interact with HLA-C group 
2 alleles and involved in the killing of leukemic blasts from HLA-C2 patients. The interaction 
between KIR2DS1 and HLA-C2 was found to overcome NKG2A mediated inhibitory signals 
in vitro [113, 114]. These results suggested KIR2DS1-mediated activating signal may break 
the barrier of NKG2A and exert positive effect during HSCT. Venstrom et al. investigated 
the role of KIR2DS1 from donor in unrelated HSCT in 1277 patients with AML and found 
that KIR2DS1 expression in donor mediated a significant GvL effect [114]. Notably, no ben-
eficial effect was observed when donors were HLA C2 homozygous as in those donors, NK 
cells expressing KIR2DS1 cannot be educated and acquire effector function. Therefore, at least 
one copy of HLA-C1 in donor is needed for KLR2DS1-dependent GvL effect. In addition, 
KIR3DS1 was also found to associate with lower rate of relapse and infection. Mancusi A et al. 
reported KIR3DS1 was associated with reduced infection mortality [115]. Further studies are 
still needed to identify ligands for activating KIR so as to confirm the effect of each activating 
KIR gene on allo-HSCT outcome.
The intensity of interaction between KIR and HLA may also influence the alloreactivity of NK 
cells during allo-HSCT. HLA alleles have been shown to bind NK cells with different affinities. 
The HLA class I molecules are highly polymorphic, and HLA-B alleles can be divided into 
HLA-B alleles with an isoleucine at position 80 (80I) and with a theonine (80T). The affinity 
between certain HLA-B alleles with an 80I and KIR3DL1 was found to be much stronger than 
those with an 80T [116, 117]. The impact of this different affinity was tested in HIV patients 
[118]. Presence of 80I but not 80T in HIV patients associated with slower AIDS progression. 
These results indicated strong interaction with KIR3DL1 may promote NK cell education 
and enhance their effector function. HLA-C1 alleles can also bind to NK cells with different 
affinity [119]. Donors who were homozygous for HLA-C*07 produce higher level of IFN-γ 
compared to donors expressing either HLA-C*01, 03*,*08, *1402, or 1403*. Since the strength 
of the interaction between KIR and HLA is critical for NK cell education and function, it is 
tempting to speculate that during allo-HSCT certain HLA combination may enhance NK cell 
activity and contribute to better outcome of HSCT. The differing KIR/HLA affinity also can be 
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generated by KIR allelic differences. KIR3DL1 is one of the most polymorphic KIR genes with 
more than 60 alleles [120]. KIR3DL1*01052 binds to Bw4 more firmly than KIR3DL*007 due to 
their high-expression level [119]. Although the surface expression of KIR3DL1*002 is similar 
to KIR3DL*007, the former generates stronger interaction with Bw4 than the latter [121]. KIR-
recognizing HLA-C alleles also have varying interactions. KIR2DL1 has been shown to be the 
strongest KIR for HLA-C2 followed by KIR2DL2 then KIR2DL3 [122]. These differing affini-
ties may explain the beneficial effect of haplotype B from donors as these donors are homozy-
gous for KIR2DL2 which may account for the generation of NK cells with enhanced function.
Besides using “missing self” model to predict alloreactivites of NK cells as described above, 
“missing ligand” model has also been used to speculate alloreactivites. According to this 
model, NK cell alloreactivity may also be observed when the KIR on the surface of donor 
NK cells cannot recognize the ligands either from donor or recipient [123, 124]. As we have 
mentioned, these “unlicensed” NK cells are hyporesponsive in situ but can have potential 
to acquire effector function in recipients. Thus, NK cell alloreactivity can occur even after 
autologous HSCT. This model is supported by the observation that most individuals have 3 
inhibitory KIR, but only 1 or 2 corresponding HLA KIR ligands are expressed on the surface 
of their own cells [125, 126]. Several comparative analyses have been performed to test the 
prediction rate of this model. Some groups found the selection of donors based on this model 
indeed was associated with better outcome, while others reported opposite results [127–129]. 
These variable results may be due to the complexity and variables of HSCT.
6. The impact of cytomegalovirus infection on natural killer  
cell-mediated graft-versus-leukemia effect: reconstitution  
promotion and memory induction
6.1. The impact of cytomegalovirus infection on natural killer cell reconstitution
Although in healthy individuals, CMV infection is potentially controlled by T cells and NK 
cells, it can cause life-threatening complication in immunodeficient transplant recipients. 
Lethal CMV-caused illness is now uncommon thanks to the use of drugs such as ganciclovir 
and foscarnet. In view of the strong immune response caused by CMV, it is attractive to inves-
tigate whether CMV reactivation can reduce the risk of relapse in patients after HSCT. As 
early as 30 years ago, Lonnqvist et al. reported that CMV infection was associated with lower 
relapse in BMT recipients with various hematological malignancies [130]. Subsequently, a 
number of reports confirmed that CMV reactivation following HSCT resulted in reduced 
relapse in AML patients. Among these reports, Elmaagacli et al. found CMV reactivation 
occurred within the first 100 days after HSCT significantly reduce the rate of AML relapse 
from 42 to 9% [131]. Remarkably, this CMV reactivation-mediated relapse prevention effect 
was independent of aGvHD. Furthermore, in another study of large cohort of 2566 patients 
with variable hematological malignancies, Green et al. comprehensively analyzed the results 
among all kinds of disease with adjustment for potential variables and reported that CMV 
reactivation was significantly associated with a decreased risk of relapse [132].
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Upon the association between CMV reactivation and decreased rate of relapse after HSCT 
was confirmed, several studies next tried to test whether CMV-specific donor T cells 
accounted for this beneficial effect. However, CMV-specific donor T cells appeared not 
to impact relapse rates after HSCT [133]. On the other hand, NK cells have been shown to 
play an important role in CMV reactivation-mediated relapse prevention. Foley et al. dem-
onstrated that the beneficial effect of CMV reactivation was specifically associated with the 
clonal-like expansion of NK cells characterized by the NKG2C+ NKG2A− self-KIR+ CD57+ 
CD56dim signature [80]. These NK cells have been shown to exhibit enhanced cytolytic 
activity and cytokine production. During CMV reactivation, both NKG2C+ NK cell percent-
ages and numbers are significantly increased with enhanced capability of producing IFN-γ 
upon the stimulation of myeloid leukemia cell line K562. Nevertheless, the mechanisms 
underlie the increased expansion and functions of NKG2C+ NK cells are not entirely clear. 
Guma et al. reported that after ex vivo stimulation with CMV-infected fibroblasts, NKG2C+ 
NK cells from seropositive healthy donors rapidly proliferated [134]. These results indi-
cated that NKG2C may play a unique role in NKG2C+ NK cell expansion. However, the 
exact ligands of NKG2C on CMV infected cells are not completely confirmed. Although 
HLA-E has been shown to be a ligand for NKG2C [135], other undefined ligands may 
also take part in NKG2C-mediated effect. Leukemic cells can retain HLE expression while 
downregulate the level of classical class I HLA molecule [136]. Therefore, it is now believed 
that the change in receptor repertoire from inhibitory receptor NKG2A to activating recep-
tor NKG2C may play a crucial role in this NK cell subset-mediated GvL effect [137].
It has been shown that NK cells from UCB transplants will undergo slower reconstitution 
compared with NK cells from adult grafts. In contrast, in CMV-infected UCB transplantation 
patients, NK cells are found to reconstitute rapidly with decreased NKG2A expression and 
increased KIR expression [138]. Their functional reconstitution is also promoted as they can 
produce high level of IFN-γ in response to K562 cells. Intriguingly, during CMV-infected 
UCB transplantation, Della Chiesa et al. detected a unique subset of hyporesponsive NK cells 
which shared similar surface markers with the expanded NKG2C+ NK cells except for CD56 
expression [139]. Briefly, this NK cell subset does not express CD56. IL-2 stimulation can 
reverse the hyporesponsive state of CD56− NK cells thereby this NK cells subset may repre-
sent a stage of NK cell differentiation in the case of cytokine deficiencies.
The effect of CMV reactivation was also investigated in recipients received grafts either from 
peripheral blood or bone marrow [140]. Strikingly, the expansion of NKG2C+ NK cells seemed 
to be dependent on the serostatus of recipient. The percentage of NKG2C+ NK cells was sig-
nificantly increased when CMV seropositive recipients received grafts from CMV seronega-
tive donors. Oppositely, when grafts from CMV seropositive donors were infused into CMV 
seronegative recipients, NKG2C+ NK cells failed to expand, and their percentage was declined 
to the levels similar to CMV seronegative donor/recipient pairs.
Besides NKG2C, activating KIR may also contribute to CMV-induced NK cell expansion. Della 
Chiesa et al. proved that when donor grafts were lack of NKG2C, NKG2C− NK cells can rapidly 
expanded expressing activating KIR in the recipients following CMV infection [141]. These 
data indicated that activating KIR can recognize CMV and promote NK cell reconstitution 
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independent of NKG2C. Correspondingly, the increased presence of donor activating KIR 
has been shown to result in reduced risk of CMV infection [142, 143]. However, the ligands 
expressed on the CMV infected cells specific for activating KIR are still elusive, which become 
an obstacle to explore the actual role of activating KIR in CMV-infected HSCT.
Additionally, CMV seropositivity has been shown to be associated with presence of a popula-
tion of NK cells which does not express FcγRIγ [144]. FcγRIγ is an adapter molecule that is used 
by CD16, NKP30, and NKp46 for signal transmitting. CD3ζ is also required for CD16 associated 
signal transduction. Lack of both FcγRIγ and CD3ζ in HIV-infected patients was proved to 
diminish CD16 signaling [145], while single down-regulation of FcγRIγ in CMV seropositive 
healthy donors resulted in enhanced CD16 signaling [146]. The deficiency of FcγRIγ induced NK 
cells hyporesponsive to CMV infected fibroblasts, whereas CMV specific antibody can reverse 
NK cells to degranulate and produce IFN-γ and TNF-α against CMV infected fibroblasts.
6.2. Cytomegalovirus infection induces natural killer cell memory
Although traditionally viewed as a member of innate immune cells, NK cells have been 
demonstrated to mount memory response to hapten and mediate hapten-induced contact 
hypersensitivity responses [21]. In MCMV model, NK cells were also observed to develop 
memory-like properties including viral ligand m157 specific expansion, persisting over time 
and enhanced effector function after rechallenge with MCMV [22, 23]. This MCMV-induced 
memory-like population of NK cells is characterized by the expression Ly49H. Intriguingly, 
during acute human CMV, the expanded NKG2C+ NKG2A− self-KIR+ CD57+ CD56dim NK cells 
which we have described above was proved to be human analog of Ly49H+ memory-like 
NK cells [139, 147]. After HSCT, these CMV-specific memory-like NK cells can be detected 
in peripheral blood of CMV-infected HSCT recipients. As we have mentioned, when CMV-
seropositive recipients received grafts from CMV-seropositive donors, these NKG2C+ NK 
cells underwent expansion even in the absence of detectable viremia, which meant a nonclas-
sical recall response was developed [140]. However, the mechanisms underlined the genera-
tion of memory NK cells have not been exactly defined. Recently, two studies demonstrated 
that CMV infection resulted in modified effector function through driving epigenetic altera-
tions in these “adaptive” NK cells [148]. These memory-like NK cells were proved to lack 
expression of signaling proteins such as Fc epsilon receptor I (FcεRIγ), spleen tyrosine kinase 
(Syk), ewing’s sarcoma-associated transcript 2 (EAT2) and exhibit increased capacity to medi-
ate ADCC as well as produce IFN-γ in response to tumor targets. In contrast, memory-like 
NK cells produced extremely less level of IFN-γ in response to cytokines such as IL-12 and 
IL-18 mainly due to the downregulation of cytokine receptors.
In summary, NKG2C+ NK cells expanded after CMV-infected HSCT display memory-like 
properties and associated with reduced risk of relapse. Nevertheless, it is still unclear whether 
the GvL effect observed in CMV-infected HSCT is mainly due to NKG2+C NK cells cytotoxic-
ity toward leukemic blasts or primarily due to the cytolytic effect of CMV. This potent effect 
of CMV reactivation in shaping immune response after HSCT may provide new choice for 
therapeutic strategies, such as utilizing CMV vaccine to mimic this beneficial effect, isolating 
NKG2C+ NK cells for adoptive transfer setting and optimizing the criterion for donor selection.
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7. The effects of natural killer cells on graft-versus-host disease
Allo-HSCT has curative potential through donor immune effectors-mediated GvL effects. 
However, the donor versus host direction effect of alloreactive T cells also causes GvHD 
which is a major complication of allo-HSCT [2]. Depletion of donor T cells in grafts and appli-
cation of immunosuppressive pretreatment are often used to eliminate GvHD; however, these 
treatments also hampers GvL effects at the same time. NK cells have also been shown to play 
an important role in GvHD. In murine models, alloreactive NK cells are shown to kill anti-
gen presenting cells (APCs) thereby prevent the initiation of aGvHD [100]. Correspondingly, 
another study demonstrated that alloreactive NK cells can be recruited into the lymph nodes 
and suppress T cells activation through cytotoxicity toward allogeneic dentritic cells (DCs) 
[149]. Donor NK cells may also mediate suppression of aGvHD through the direct killing 
of activated donor alloreactive T cells [150]. The possible mechanism involves the interac-
tions between activating receptor NKG2D and its ligand highly expressed on the surface of 
activated T cells, which help NK cells to discriminate activated T cells from normal T cells 
and initiate killing [151, 152]. NK cells were also found to inhibit aGvHD through cytokine 
production such as TGF-β [153]. Furthermore, NK cells were able to inhibit the proliferation 
of donor CD4+T cells and reduce the risk of cGvHD [154]. Remarkably, donor NK cells are 
believed not to attack normal host tissues mainly due to the absence of activating receptor 
ligands on normal nonhematopoietic cells [155].
Although these previous experimental studies suggested that donor NK cells may have poten-
tial role in modulating GvHD, the clinical results are variable. Ruggeri L et al. reported NK 
cell alloreactivity was favorably associated with the lower risk of aGvHD [6]. However, this 
benefit effect cannot be observed in most groups, some groups even found KIR mismatch may 
worsen GvHD [156, 157]. Notably, in a recent clinical trial, IL-15/4-1BBL-activated donor NK 
cell infusion was found to contribute to aGvHD in T-cell depleted HSCT [158]. Collectively, 
these contradictory results indicated the role of alloreactive NK cells in GvHD may be vari-
able. They could either aggravate or attenuate GvHD probably depended on different immune 
microenvironment in HSCT. Correspondingly, in our study of murine acute GvHD model, 
IL-12/15/18-preactivated donor NK cells significantly inhibited severe aGvHD, whereas they 
accelerated the development of aGvHD in a mild aGvHD model (unpublished data).
8. Donor selection based on killer cell immunoglobulin-like  
receptor typing
Since alloreactive NK cells play a critical role in the successful treatment of leukemia patients 
receiving alloreactive grafts, it is crucial to ensure sufficient number of NK cells in the best 
possible donor. As we have discussed above, the polymorphisms of KIR and its ligand HLA 
obviously affect NK cell alloreactivity. Therefore, genotyping of these two families of genes 
provides the probability to identify the size of alloreactive NK cell populations in donor. Up to 
now, there are three levels of KIR typing. The first level is genotyping to test the gene content of 
KIR families [159]. Based on these results, the KIR haplotype of donor is confirmed and scored. 
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The preferable donors defined in this level are those possess inhibitory KIR specific for HLA-I 
alleles absent in the recipients with highest haplotype B score [128, 160]. The second level of KIR 
typing is using flow cytometry and quantitative PCR to assess the number of KIR mismatched 
NK cells and the expression of KIR gene [125]. Based on the results of this level, the donors 
possess the largest number of KIR mismatched NK cells with high frequency of KIR gene 
expression are preferable. The third level is KIR typing of alleles [161]. As we have discussed 
above, different alleles of KIR gene may result in different intensity of NK cell alloreactivity. 
Therefore, donors with stronger KIR alleles should be selected. Finally, FcγR polymorphisms 
are also needed to analyze when the treatment is associated with ADCC effect of NK cells [162]. 
Additionally, the assess of NK cell cytotoxicity toward leukemic blasts from patients could also 
help to predict the outcome of HSCT.
9. Adoptive transfer of donor natural killer cells and natural  
killer cell expansion
Despite their potential beneficial role in allo-HSCT, donor NK cells derived from the hema-
topoietic stem cells may be functionally impaired due to their immaturity and insufficient 
education. Thus, adoptively transfer of mature donor NK cells has been employed to pro-
vide the immunotherapeutic benefits for allo-HSCT. The first trial of utilizing allogeneic 
NK cells as immunotherapy in humans was published in 2005 focused on the impact of 
different chemotherapy preparative regimens on infused donor NK cells [163]. Three differ-
ent chemotherapy preparative regimens were used in their study: high cyclophosphamide 
and fludarabine (Hi-Cy/Flu), low cylcophosphamide and methylprednisone, or fludarabine 
alone. Their results demonstrated that the infusion of NK cells was well tolerated by patients, 
donor-derived NK cells expansion can only be detected in patients receiving Hi-Cy/Flu. 
Furthermore, long-term remission was observed in 5 of 19 patients. An obvious increase 
in endogenous IL-15 concentration was detected in patients receiving high intensity of the 
conditioning regimen and was associated with the expansion of adoptive transferred donor 
NK cells. These results indicated the Hi-Cy/Flu treatment may eliminate recipient’s lympho-
cytes thereby provide “space” and adequate cytokines for expansion of transferred donor 
NK cells. These results also suggested besides IL-2, IL-15 might be a good choice to promote 
NK cell expansion in vivo. In the follow-up study, the criteria for successful donor NK cell 
expansion were defined as a measurement of more than 100 donor NK cells/μl of peripheral 
blood 12–16 days after infusion [113].
Although remission of patients was observed in the above studies, this benefit effect was 
not permanent as patients ultimately relapsed. To test whether host-mediated rejection 
affected the expansion of donor NK cells thereby resulted in remission, total body irradia-
tion was added to Hi-Cy/Flu to deplete recipient cells [138]. The results demonstrated that 
measurable NK cell expansion was obviously increased in patients received total body irra-
diation, which was associated with better leukemia clearance effect. These data again indi-
cated the importance of enough “space” for successful expansion of donor NK cells during 
HSCT. In a pediatric study, Rubnitz et al. reported after high intensity of lymphodepeleting 
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chemotherapy, infused donor NK cells could successfully expand in the patients of AML 
[164]. Remarkably, among 10 patients, three patients were observed to have detectable NK 
cells up to 1 month after infusion and have a disease-free survival rate of 100% at a median 
of 2 years. This promising outcome may due to the higher cell dose of transferred donor 
NK cells used in this study; thus, higher doses of infused NK cells may be important for 
better HSCT outcome.
To produce sufficient number of donor NK cells and achieve the optimal expansion of NK 
cells ex vivo, numbers of studies were performed with variable approaches, such as cytokine 
stimulation and utilizing engineered feeder cells. Up to now, clinical NK cell doses can be 
reached even up to 108 NK cells/kg [165]. However, there are numerous factors that may 
affect the effector function of expanded NK cells. A crucial factor among these complicated 
production protocol is how to activate NK cells ex vivo. Addition of cytokines such as IL-2 or 
IL-15 was used to promote survival and expansion of NK cells. Although IL-2 stimulation 
may result in activation-induced cell death (AICD) of NK cells in vivo, IL-15 stimulation 
does not have this side effect [166, 167]. Subsequently, human-derived feeder cells were 
used to develop approaches in expanding NK cells. Fujisaki et al. first reported the use of 
genetically modified APCs that could expand NK cells from peripheral blood 500- to 1000-
fold [13]. These artificial APCs can be further modified with costimulatory molecules and 
membrane-bound cytokines [168, 169]. The expanded NK cells express high level of activat-
ing receptors and CD16 molecule and are proved to be potent mediators of cytotoxicity. 
However, these activated NK cells often become “exhausted” and cannot maintain their 
effector function and expansion in vivo [170]. Denman CJ et al. used APCs modified with 
membrane-bound form of IL-21 to break this barrier [168]. However, after cytokine with-
drawal, these ex vivo expanded NK cells have been shown to have shorter survival in vivo 
compared with freshly activated NK cells [171].
Another alternative approach is to generate “memory-like” NK cells ex vivo. Cooper et al. 
reported that IL-12/15/18-preactivated NK cells obtained the ability to produce increased 
IFN-γ upon restimulation for up to 4 months after adoptive transfer [24]. Therefore, cyto-
kine preactivation before infusion may amplify and sustain the beneficial effects of NK cells 
during allo-HSCT. The enhanced antitumor activity of murine IL-12/15/18-preactivated 
NK cells was first demonstrated in a murine tumor model [172]. Similar to murine NK 
cells, human IL-12/15/18-preactivated NK cells have been recently shown to have memory-
like properties, including increased IFN-γ production, enhanced proliferation, and high 
expression of IL-2 receptor [26]. Recently, a phase I study of adoptively transferred cyto-
kine-induced memory-like NK cells has demonstrated sustained anti-leukemia responses in 
patients with relapsed or refractory AML [173]. Therefore, cytokine-induced memory-like 
NK cells may possess long-lasting effector function in vivo, which can be harnessed in the 
treatment of leukemia patients. However, the safety of such therapy could be complicated 
by the induction of aGvHD after allo-HSCT. Adoptively transfer of donor-derived IL-15/4-
1BBL-activated donor NK cells contributed to aGvHD [158], likely through upregulation of 
activating receptor expression and inflammatory cytokine production. Therefore, the effect 
of IL-12/15/18-preactivated NK cell infusion on GvL and GvHD after allo-HSCT needs fur-
ther investigation.
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10. Methods to enhance natural killer cell function and  
future perspectives
Monoclonal antibodies are now increasingly being studied for their effect on enhancement of 
NK cell activity. The isotype IgG1 subclass is often used to induce ADCC through stimulating 
activating Fc receptors on NK cells. The most effective monoclonal antibody used in hemato-
logical malignancy is Rituximab, which targets antigen CD20 on B cells [174]. Notably, it was 
proved that such antibodies should be administered at appropriate time point as NK cells 
reconstituted early after HSCT are immature with lower expression of CD16 [95]. Interactions 
between inhibitory KIRs and HLA molecules transmit a potent inhibitory signal to the NK 
cell, thus monoclonal antibodies blocking inhibitory KIR receptors are used to enhance NK 
cell activity. The preclinical results demonstrated these antibodies appear safe and do not 
induce autoimmunity [175]. Additionally, a disintegrin and metalloprotease-17 (ADAM17) 
was demonstrated to induce activated NK cells to lose expression of CD16 and CD62L [176]. 
Therefore, pharmacologic inhibition of ADAM17 is used to enhance the cytotoxicity of NK 
cells toward Rituximab bound lymphoma cells. Following the improvement of antibody pro-
duction, bispecific killer engagers (BiKE) and trispecific killer engagers (TriKE) are used to 
crosslink specific tumor antigens such as CD19, CD20 with a potent stimulator on NK cell 
such as CD16 [177–179]. CD16 × 19 BiKEs and CD16 × 19 × 22 TriKEs have been constructed 
and shown to significantly activate CD16 signaling of NK cells [180, 181]. Furthermore, a 
CD16 × 33 BiKEs was constructed recently and proved to result in potent cytotoxicity of 
NK cells in patients of refractory AML [182]. However, the very short half-life of bi- and tri-
specific antibodies might limit their therapeutic effect [179].
Another important focus is to enhance the immune response of NK cells through sensitiz-
ing target cells. Bortezomib is a drug classically used to treat multiple myeloma and mantle 
cell lymphoma. As a proteosome inhibitor, Bortezomib can sensitize tumor cells to TRAIL-
mediated apoptosis [14]. Moreover, drugs such as doxorubicin and depsipeptide have been 
proved to upregulate the expression of death receptors including Fas, TRAIL-R1, TNFR1, 
thereby sensitize tumor cells to the cytotoxicity of NK cells [183, 184].
Recently, NK cells are also genetic engineered to express CARs which represent an effective 
therapy. The preclinical studies demonstrated that primary NK cells expressed CAR con-
structs can result in potent killing of B cell tumors [185, 186]. However, it is difficult to express 
exogenous genes in primary NK cells and to reach enough number for immunotherapy. 
Therefore, human NK-like cell line, NK-92 becomes another candidate for genetic engineer-
ing. Based on the results of phase I clinical trials of NK-92 cells [187], CAR-expressing NK-92 
cells may be easily expanded ex vivo and well tolerated in patients.
11. Conclusions
A number of recent studies demonstrated that NK cells played a critical role in disease-
relapse prevention. Based on the progress made in the field of NK cell therapy, the criteria 
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for choosing HSCT donor have been significantly changed and shown to be associated with 
better outcomes. However, the role of NK cells in HSCT is not fully understood. The GvL 
effect of NK alloreactivity may be affected by the complexity of HSCT including the degree of 
T-cell depletion, donor sources, degree of HLA mismatch, different intensity of preparative 
regimens, and the origin of leukemic blasts. Furthermore, the haplotype of donor KIR genes 
and the intensity of interaction between KIR and HLA may also influence the GvL effect of 
NK cells. Donor KIR B haplotype may be favorably associated with better overall survival. 
The education of NK cells is also critical for their beneficial effect. The stronger KIR/HLA 
affinity may contribute to the generation of NK cells with enhanced GvL effect. Intriguingly, 
“unlicensed” NK cells may also have chance to undergo “re-education” and acquire potent 
effector function after HSCT. Several studies reported the favorable association between CMV 
reactivation and better HSCT outcome. This beneficial effect of CMV reactivation was mainly 
due to the expansion of NKG2C+ NK cells. Moreover, these NKG2C+ NK cells display mem-
ory-like properties and enhanced cytotoxicity toward leukemic blasts. NK alloreactivity has 
been demonstrated to play potential role in suppression of aGvHD. However, some groups 
found KIR mismatch or alloreactive donor NK cell infusion also worsen aGvHD. Therefore, 
the role of NK alloreactivity in GVHD still needs to be carefully studied.
Since the GvL effect of NK alloreactiviy is affected in various aspects. Some critical questions 
are still remained to answer so as to ensure NK cells play the most desirable role during 
HSCT. The fate of NK cells is still unpredictable after transfusion. The optimal approach to 
expand most powerful NK cells which can maintain their proliferative potential and effector 
function in vivo is still not confirmed. The risk of the clinical usage of these activated NK cells 
is still needed for evaluation. The ligands of several activating receptors are undefined and 
the interactions between NK cells and other immune cells need further investigation. Further 
studies are also required to explore the mechanism underlying the process of NK cell “educa-
tion” and “memory”. Recently, monoclonal antibodies and immunomodulatory drugs are 
utilized to modulate NK cell function and proved to have benefit effect on the outcome of 
HSCT, whereas it is still needed to confirm the suitable hematopoietic malignancies for these 
treatments. The answers to these questions and continuous progress in understanding NK 
cells biology will optimize donor NK cells-based therapy and benefit the outcomes of HSCT.
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